Skip global navigation and go to header navigation

Skip global navigation and read the article

Skip global navigation and go to local navigation

Skip global navigation and go to footer navigation



Home > Corporate Profile > Business Field > Research and Development

Research and Development


Zeria Group’s Research and Development

Zeria is promoting efficient and steady new drug development in Japan and overseas that includes actively allocating management resources to R&D and undertaking global clinical trials.

Ethical Drug Development

Zeria has built a pipeline focused on the gastrointestinal field and oncology field and launched numerous pharmaceutical products throughout the world, including Acofide, an original first-in-class therapeutic agent discovered and developed by Zeria for functional dyspepsia. Additionally, we are actively in-licensing and developing drugs that have sales track records in overseas markets with the aim of contributing to medical care.

Swiss-based Tillotts Pharma, a Zeria Group company and the originator of the ulcerative colitis therapeutic agent Asacol, is carrying out business centering on lower gastrointestinal tract treatments. Tillotts Pharma also proactively undertakes clinical development to raise the added value of products, which includes developing improved-version mesalazine formulations utilizing new formulation technologies and adding new dosage forms.

Aiming for Efficient Global Development

In 2018 Zeria and Tillotts Pharma built a new organization that unifies the management of R&D at both companies, with the aim of achieving efficient global development.

The management under this new organization will control the Zeria Group’s global development, thereby enabling the Group to strengthen its new drug pipeline. The Zeria Group aims to raise its global R&D capabilities to steadily provide treatments as quickly to possible to patients fighting illnesses.

Developing Consumer Healthcare Products that Satisfy Customer Needs

Consumer Healthcare product development aims at developing products that match customer needs in a broad range of categories. These include OTC drugs that contribute to self-medication as well as quasi-drugs, cosmetics, health foods and medical devices that support extended healthy lifespans.

Research and Development Pipeline

UP DATE 2-Aug-19

1. Domestic

Stage Development Code/
Generic Name
Development Indications Classsification Origin
NDA approved Z-213
Ferric carboxymaltose
(Brand Name: Ferinject solution for injection/infusion 500mg)
Zeria Iron deficiency anemia Intravenous iron replacement In-licensed
Phase III
(Asia Global Development)
Z-100 Zeria Cervical cancer Immunomodulator Original
Phase II ZG-801
Patiromer
Zeria Hyperkalemia Potassium binder In-licensed

2. Overseas

Stage Development Code/
Generic Name
Development Indications Classsification Origin
NDA filed
(China)
Z-206
Mesalazine
Zeria·Tillotts Pharma AG co-development Ulcerative colitis Targeted local, colonic, anti-inflammatory with pH dependent controlled-release formulation Original
(Tillotts Pharma AG)
Phase III
(Europe)
Z-338
Acotiamide
Zeria Functional dyspepsia Upper gastrointestinal motility modulator Original
Phase III
(Asia)
Z-100 Zeria Cervical cancer Immunomodulator Original

3. Launched in Overseas

Launch Date Development Code/ Generic Name Development Indications Classification Origin
December 2018 in Europe TP05
Mesalazine
Tillotts Pharma AG Ulcerative colitis Targeted local, colonic, anti-inflammatory with OPTICORE™ formulation Original (Tillotts Pharma AG)